Formulation and characterization of nanoliposomal 5-fluorouracil for cancer nanotherapy

被引:42
作者
ElMeshad, A. N. [1 ]
Mortazavi, S. M. [2 ]
Mozafari, M. R. [3 ]
机构
[1] Cairo Univ, Dept Pharmaceut & Ind Pharm, Fac Pharm, Cairo, Egypt
[2] Kurdestan Univ, Fac Med, Med Sch Sanandaj, Biochem Grp, Sanandaj, Kurdestan, Iran
[3] Monash Univ LPO, Australasian Nanosci & Nanotechnol Initiat, Clayton, Vic 3800, Australia
关键词
Cancer nanotherapy; 5-fluoruracil; heating method; lipid vesicles; transmission electron microscope; CELL LUNG-CANCER; DRUG-DELIVERY; VESSEL LEAKINESS; DNA COMPLEXES; LIPOSOMES; CHEMOTHERAPY; STABILITY; TOXICITY; INFUSION; SYSTEMS;
D O I
10.3109/08982104.2013.810644
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A scalable and safe method was developed to prepare nanoliposome carriers for the entrapment and delivery of 5-fluorouracil (5-FU). The carrier systems were composed of endogenously occurring dipalmitoylphosphatidylcholine (DPPC), negatively charged dicetylphosphate (DCP), cholesterol (CHOL) and glycerol (3%, v/v). Nanoliposomes were prepared by the heating method in which no harmful chemical or procedure is involved. Results indicated fast and reproducible formation of non-toxic liposomes that possess high entrapment efficiency (up to 96.9%) and vesicle size range of ca. 530-620 nm. Transmission electron and optical micrographs of the 5-FU liposomes revealed that they were spherical and some were multilayered. There was an increase in the release rate of 5-FU from the liposomes prepared with a high ratio of drug: lipid. The release data showed that the highest release rates were obtained for nanoliposomes containing 5-FU with the drug concentration of 500 mM and that it followed the diffusion model. Nanoliposome preparation method introduced here has the potential of large-scale manufacture of safe and efficient carriers of 5-FU.
引用
收藏
页码:1 / 9
页数:9
相关论文
共 66 条
[1]   Drug delivery systems: Entering the mainstream [J].
Allen, TM ;
Cullis, PR .
SCIENCE, 2004, 303 (5665) :1818-1822
[2]  
[Anonymous], CANC MED
[3]   ABSORPTION OF 5'-DEOXY-5-FLUOROURIDINE FROM COLON [J].
AU, JLS ;
GUNNARSSON, LC .
PHARMACEUTICAL RESEARCH, 1989, 6 (04) :323-327
[4]  
CHABNER BA, 1982, PHARM PRINCIPLES CAN, P132
[5]  
Chandrashekar NS, 2007, J HEALTH SCI, V53, P275
[6]   CONTINUOUS INTRAVENOUS-INFUSION OF 5-FLUOROURACIL IN THE TREATMENT OF REFRACTORY BREAST-CANCER [J].
CHANG, AYC ;
MOST, C ;
PANDYA, KJ .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1989, 12 (05) :453-455
[7]   Airway delivery of cationic lipid: DNA complexes for cystic fibrosis [J].
Cheng, SH ;
Scheule, RK .
ADVANCED DRUG DELIVERY REVIEWS, 1998, 30 (1-3) :173-184
[8]  
Chew NYK, 2002, J PHARM PHARM SCI, V5, P162
[9]   Preparation of liposomes by reverse-phase evaporation using alternative organic solvents [J].
Cortesi, R ;
Esposito, E ;
Gambarin, S ;
Telloli, P ;
Menegatti, E ;
Nastruzzi, C .
JOURNAL OF MICROENCAPSULATION, 1999, 16 (02) :251-256
[10]  
Curreri A, 1985, CANCER RES, V18, P478